Last reviewed · How we verify
Nanocort
Nanocort is a Small molecule drug developed by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). It is currently in Phase 1 development. Also known as: Nanocort (PEG-liposomal prednisolone sodium phosphate)..
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nanocort |
|---|---|
| Also known as | Nanocort (PEG-liposomal prednisolone sodium phosphate). |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation (PHASE2)
- Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) (PHASE2)
- A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort (PHASE1, PHASE2)
- Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nanocort CI brief — competitive landscape report
- Nanocort updates RSS · CI watch RSS
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) portfolio CI
Frequently asked questions about Nanocort
What is Nanocort?
Who makes Nanocort?
Is Nanocort also known as anything else?
What development phase is Nanocort in?
Related
- Manufacturer: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Nanocort (PEG-liposomal prednisolone sodium phosphate).
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing